{
    "clinical_study": {
        "@rank": "75417", 
        "arm_group": [
            {
                "arm_group_label": "SYL040012 eye drops dose A", 
                "arm_group_type": "Experimental", 
                "description": "Ocular topical administration of SYL040012 eye drops dose A"
            }, 
            {
                "arm_group_label": "SYL040012 eye drops dose B", 
                "arm_group_type": "Experimental", 
                "description": "Ocular topical administration of SYL040012 eye drops dose B"
            }, 
            {
                "arm_group_label": "SYL040012 eye drops dose C", 
                "arm_group_type": "Experimental", 
                "description": "Ocular topical administration of SYL040012 eye drops dose C"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Ocular topical administration of placebo eye drops"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this dose-finding clinical trial is to evaluate the systemic tolerability, local\n      tolerability and intraocular pressure lowering effect of three different doses of SYL040012\n      in subjects with ocular hypertension or open-angle glaucoma."
        }, 
        "brief_title": "Dose Finding Clinical Trial With SYL040012 to Evaluate the Tolerability and Effect on Intraocular Pressure in Subjects With Ocular Hypertension or Open Angle Glaucoma", 
        "completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Ocular Hypertension", 
            "Open Angle Glaucoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Glaucoma", 
                "Glaucoma, Open-Angle", 
                "Hypertension", 
                "Ocular Hypertension"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects must provide signed informed consent prior to participation in any\n             study-related procedures.\n\n          -  Male and female subjects in good or fair general health as assessed by the\n             investigator.\n\n          -  \u226518 years of age.\n\n          -  Previous history or newly diagnosed elevated IOP (\u226521 mmHg) with or without\n             open-angle glaucoma in both eyes.\n\n          -  Normal result, or result typical for open-angle glaucoma of the following assessments\n             in both eyes or available results in writing within the last 3 months prior to\n             baseline period i.e. up to 4 months before Day 1, on condition that no new ocular\n             signs or symptoms (e.g. marked deterioration of vision, eye pain) has occurred since\n             then which would justify a repeat examination:\n\n          -  Visual field 24-2 or equivalent\n\n          -  Optical coherence tomography (OCT)\n\n          -  Best corrected visual acuity \u22650.5 (20/40) on the Snellen chart, or \u2264 0.3 logMAR\n\n          -  Schirmer test (lacrimation)\n\n          -  Funduscopy\n\n        Exclusion Criteria:\n\n          -  Pregnant or breastfeeding females or those with a positive pregnancy test. Females of\n             childbearing potential who will not use a medically acceptable contraceptive method\n             from selection and during the hole study.\n\n          -  Females of childbearing potential not willing to use a medically acceptable\n             contraceptive method from enrolment until after the follow-up visit.\n\n          -  Any current disease or condition that might compromise the respiratory,\n             cardiovascular, endocrine, neurological, haematological, renal, or gastrointestinal\n             function.\n\n          -  Previous chronic processes or with rebound characteristics that could interfere with\n             the study according to the investigator's judgment.\n\n          -  Body temperature.\n\n          -  Intolerability of any components of SYL040012 or placebo.\n\n          -  Unable to comply with the clinical trial requirements as judged by the investigator.\n\n          -  Beta blockers or corticosteroids use (other than cutaneous or intra-articular) for\n             the treatment of concurrent diseases, even if sporadically, or any ocular or nasal\n             vasoconstrictor treatment in the last 15 days prior to the first investigational\n             product administration\n\n          -  Previous refractive surgery; cataract extraction in the last 6 months\n\n          -  Previous surgery for glaucoma.\n\n          -  Participation in a clinical trial within 2 months before the enrolment visit\n\n          -  Use of any other investigational product within 60 days before the enrolment visit.\n\n          -  Other drugs for the treatment of concurrent diseases are allowed. However, their\n             dosages should be kept constant throughout the study.\n\n          -  Use of contact lenses in the last 7 days prior to the first investigational product\n             administration and wearing contact lenses throughout the trial\n\n          -  History of ocular infection or inflammation within the last 3 months before the\n             enrolment visit\n\n          -  Angle-closure or pigmentary glaucoma.\n\n          -  Chronic or current acute eye diseases such as scleritis, uveitis, blepharitis,\n             conjunctivitis, or ocular Herpes simplex virus infection"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 12, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01739244", 
            "org_study_id": "SYL040012_III"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "SYL040012 eye drops dose A", 
                    "SYL040012 eye drops dose B", 
                    "SYL040012 eye drops dose C"
                ], 
                "description": "Ocular topical administration of SYL040012 for 14 consecutive days", 
                "intervention_name": "SYL040012", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Ocular topical administration of placebo for 14 consecutive days", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Glaucoma", 
            "Open Angle Glaucoma", 
            "Ocular Hypertension", 
            "IOP", 
            "RNAi", 
            "siRNA", 
            "beta inhibitor"
        ], 
        "lastchanged_date": "June 7, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Tallin", 
                        "country": "Estonia", 
                        "zip": "10138"
                    }, 
                    "name": "East Tallin Central Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tallin", 
                        "country": "Estonia", 
                        "zip": "13419"
                    }, 
                    "name": "Eye Clinic Dr. Krista Turman"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Freiburg", 
                        "country": "Germany", 
                        "zip": "79106"
                    }, 
                    "name": "Universitaetsklinikum Freiburg"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "K\u00f6ln", 
                        "country": "Germany", 
                        "zip": "50937"
                    }, 
                    "name": "Uniklinik K\u00f6ln"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mainz", 
                        "country": "Germany", 
                        "zip": "55131"
                    }, 
                    "name": "Universitaetsklinikum Mainz"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pamplona", 
                        "country": "Spain", 
                        "state": "Navarra", 
                        "zip": "31008"
                    }, 
                    "name": "Clinica Universidad Navarra"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08022"
                    }, 
                    "name": "Institut Catal\u00e0 de Retina"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28041"
                    }, 
                    "name": "Hospital Universitario 12 de Octubre"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28034"
                    }, 
                    "name": "Hospital Universitario Ram\u00f3n y Cajal"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28040"
                    }, 
                    "name": "Hospital Universitario Cl\u00ednico San Carlos"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Valladolid", 
                        "country": "Spain", 
                        "zip": "47011"
                    }, 
                    "name": "Instituto de Oftalmobiolog\u00eda Aplicada"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Estonia", 
                "Germany", 
                "Spain"
            ]
        }, 
        "number_of_arms": "4", 
        "official_title": "Dose Finding Clinical Trial With SYL040012 to Evaluate the Tolerability and Effect on Intraocular Pressure in Subjects With Ocular Hypertension or Open Angle Glaucoma", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Spain: Spanish Agency of Medicines", 
                "Spain: Ethics Committee", 
                "Estonia: Research Ethics Committee", 
                "Estonia: The State Agency of Medicine", 
                "Germany: Ethics Commission", 
                "Germany: Federal Institute for Drugs and Medical Devices"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Difference in AUC between IOP Curve Obtained at the Established Time Points and the Same Curve Performed at Baseline Period", 
                "safety_issue": "No", 
                "time_frame": "14 days + (4-7 days)"
            }, 
            {
                "measure": "Simple Corneal and Conjunctival Evaluation", 
                "safety_issue": "Yes", 
                "time_frame": "15 days + (3-6 days)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01739244"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Visual acuity, anterior segment and ocular fundus examination as measures of local tolerability.", 
                "safety_issue": "Yes", 
                "time_frame": "14 days + (4-7 days)"
            }, 
            {
                "measure": "Physical exploration and laboratory tests as measurements of general tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "14 days + (4-7 days)"
            }, 
            {
                "measure": "Assessment of Adverse Events Appearance", 
                "safety_issue": "Yes", 
                "time_frame": "14 days + (4-7 days)"
            }
        ], 
        "source": "Sylentis, S.A.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sylentis, S.A.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}